CS
Candriam SCA Portfolio holdings
AUM
$17.3B
1-Year Return
21.68%
This Quarter Return
+1.91%
1 Year Return
+21.68%
3 Year Return
+102.54%
5 Year Return
+176.54%
10 Year Return
+489.52%
AUM
$14.7B
AUM Growth
+$98M
(+0.67%)
Cap. Flow
+$48.4M
Cap. Flow
% of AUM
0.33%
Top 10 Holdings %
Top 10 Hldgs %
22.12%
Holding
956
New
63
Increased
332
Reduced
303
Closed
69
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$54.5M |
| 2 |
AstraZeneca
AZN
|
$46.3M |
| 3 |
Autodesk
ADSK
|
$40.5M |
| 4 |
Mercado Libre
MELI
|
$39.4M |
| 5 |
Amazon
AMZN
|
$31.1M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$92.5M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$85.8M |
| 3 |
Alibaba
BABA
|
$60.1M |
| 4 |
Merck
MRK
|
$49.2M |
| 5 |
MXIM
Maxim Integrated Products
MXIM
|
$48.5M |
Sector Composition
| 1 | Healthcare | 32.1% |
| 2 | Technology | 24.54% |
| 3 | Financials | 9.08% |
| 4 | Communication Services | 8.24% |
| 5 | Consumer Discretionary | 7.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
IBM
IBM
$230B
| $16.4M | 0.11% |
123,843
+3,680
| +3% | +$489K |
|
202
Nucor
NUE
$33.3B
| $16.4M | 0.11% |
166,305
+142,779
| +607% | +$14.1M |
|
203
Cogent Biosciences
COGT
$1.81B
| $16.2M | 0.11% |
1,927,249
+16,529
| +0.9% | +$139K |
|
204
CBRE Group
CBRE
$48.1B
| $16.1M | 0.11% |
165,773
-153,591
| -48% | -$15M |
|
205
Synchrony
SYF
$28.6B
| $15.9M | 0.11% |
325,850
-220,592
| -40% | -$10.8M |
|
206
Becton Dickinson
BDX
$54.8B
| $15.8M | 0.11% |
65,718
| – | – |
|
207
Guardant Health
GH
$7.65B
| $15.5M | 0.11% |
124,372
+26,676
| +27% | +$3.33M |
|
208
Replimune Group
REPL
$454M
| $15.5M | 0.11% |
522,141
+36,153
| +7% | +$1.07M |
|
209
Micron Technology
MU
$139B
| $15.4M | 0.1% |
216,916
+143,596
| +196% | +$10.2M |
|
210
CEVA Inc
CEVA
$534M
| $15.3M | 0.1% |
359,669
-1,200
| -0.3% | -$51.2K |
|
211
ManpowerGroup
MAN
$1.91B
| $15.3M | 0.1% |
141,268
+63,546
| +82% | +$6.88M |
|
212
Enbridge
ENB
$105B
| $15.2M | 0.1% |
382,182
+335,491
| +719% | +$13.4M |
|
|
ATH
213
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
| $15.1M | 0.1% |
219,060
| – | – |
|
214
argenx
ARGX
$44.9B
| $15M | 0.1% |
49,526
| – | – |
|
215
DocuSign
DOCU
$15.4B
| $14.9M | 0.1% |
57,759
-5,255
| -8% | -$1.35M |
|
216
Fate Therapeutics
FATE
$112M
| $14.9M | 0.1% |
250,737
| – | – |
|
217
Norfolk Southern
NSC
$62.8B
| $14.7M | 0.1% |
61,490
-365
| -0.6% | -$87.3K |
|
218
Labcorp
LH
$22.9B
| $14.5M | 0.1% |
60,173
+7,624
| +15% | +$1.84M |
|
|
IMGN
219
DELISTED
Immunogen Inc
IMGN
| $14.5M | 0.1% |
2,562,935
+101,476
| +4% | +$575K |
|
|
CLDR
220
DELISTED
Cloudera, Inc.
CLDR
| $14.5M | 0.1% |
909,868
+136,094
| +18% | +$2.17M |
|
221
Wells Fargo
WFC
$262B
| $14.2M | 0.1% |
306,059
+71,813
| +31% | +$3.33M |
|
|
ITOS
222
DELISTED
iTeos Therapeutics
ITOS
| $14.2M | 0.1% |
525,244
+20,354
| +4% | +$550K |
|
223
DuPont de Nemours
DD
$32.3B
| $14M | 0.1% |
205,627
+2,362
| +1% | +$161K |
|
224
Zentalis Pharmaceuticals
ZNTL
$128M
| $13.9M | 0.09% |
208,526
| – | – |
|
225
Newmont
NEM
$82.3B
| $13.9M | 0.09% |
255,800
+130,403
| +104% | +$7.08M |
|